{"id":3674,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2018-03-12","marketCap":22.789289474487305,"name":"Cocrystal Pharma Inc","phone":"17864591831","outstanding":10.170000076293945,"symbol":"COCP","website":"https://www.cocrystalpharma.com/","industry":"Pharmaceuticals"},"price":2.2325,"year":2024,"month":5,"day":30,"weekday":"Thursday","title":"Historical Performance of Cocrystal Pharma Inc Stock Compared to Industry Benchmarks","date":"2024-05-30","url":"/posts/2024/05/30/COCP","content":[{"section":"Introduction","text":"Cocrystal Pharma Inc is a biotechnology company that focuses on the discovery and development of antiviral therapeutics. To evaluate the historical performance of its stock, we will compare it to industry benchmarks. This analysis aims to provide objective insights into the relative performance of Cocrystal Pharma Inc within its industry."},{"section":"Methodology","text":"For this analysis, we will consider various benchmarking indices or ETFs that represent the biotechnology sector. These benchmarks may include the iShares Nasdaq Biotechnology ETF (IBB), the SPDR S\u0026P Biotech ETF (XBI), or other relevant indices. We will compare the stock's performance over a specific period with the performance of these benchmarks over the same timeframe. The analysis will focus on key metrics such as price change, market capitalization, and relative performance."},{"section":"Performance Analysis","text":"Cocrystal Pharma Inc's stock performance will be assessed in terms of its price change compared to the benchmark indices. We will calculate the percentage change in stock price over different time periods, such as one year, three years, and five years. Additionally, we will examine the stock's market capitalization relative to the benchmark indices to determine its relative size and market position."},{"section":"Contextual Factors","text":"To provide context for the analysis, we will consider external factors that may have influenced the historical performance of Cocrystal Pharma Inc's stock. These factors may include industry trends, regulatory developments, clinical trial outcomes, or financial performance indicators specific to the company. By considering these contextual factors, we can better understand the reasons behind any observed performance disparities between Cocrystal Pharma Inc and the industry benchmarks."},{"section":"Conclusion","text":"Through a thorough analysis of Cocrystal Pharma Inc stock's historical performance compared to industry benchmarks, this study aims to provide an objective assessment of its relative performance within the biotechnology sector. By considering key metrics and contextual factors, we can gain insights into the stock's performance and its position within the industry."}],"tags":["CrossOver21","Long","Pharmaceuticals"],"news":[{"category":"company","date":1715857800,"headline":"COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344â€¦","id":127766150,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"COCP","publisher":"Yahoo","summary":"By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 2a Human Challenge Study Fully Enrolled; Topline Data Expected 2H24 On May 1, 2024, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced the completion of enrollment of 78 subjects in the Phase 2a clinical trial of CC-42344. This was a human challenge study in which study subjects were infected with influenza A","url":"https://finance.yahoo.com/news/cocp-enrollment-complete-phase-2a-111000844.html"}]}